This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
by Ahan Chakraborty
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
by Ekta Bagri
Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
by Sundeep Ganoria
MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.
MRNANegative Net Change GSKPositive Net Change PFENegative Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals vaccines
Biotech ETF (BBH) Hits New 52-Week High
by Sanghamitra Saha
BBH hits a 52-week high as positive Amgen news and strong momentum fuel gains. Can the biotech ETF rally further?
BBHNegative Net Change
biotechs etfs
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
by Ahan Chakraborty
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
BIIBPositive Net Change VKTXNegative Net Change NTLAPositive Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
by Kanishka Das
PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
PBYINegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechs
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
by Sundeep Ganoria
VKTX advances oral VK2735 into phase III as it explores weight maintenance and faces intensifying obesity drug competition.
VKTXNegative Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
by Ahan Chakraborty
LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
LLYPositive Net Change NVOPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
by Ekta Bagri
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
KYMRPositive Net Change ARVNPositive Net Change NRIXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
by Ekta Bagri
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
CYTKNegative Net Change BMYPositive Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals